ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company's lead product candidate is the Lupuzor, which has completed Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists; and the development of peptides as glucagon antagonists to treat type I and type II diabetes. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+44-20-71524080
Debt
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / BookN/A
Profitability
Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A
Miscellaneous
Employees10
OptionableNot Optionable
ImmuPharma (LON:IMM) Frequently Asked Questions
What is ImmuPharma's stock symbol?
ImmuPharma trades on the London Stock Exchange (LON) under the ticker symbol "IMM."
What price target have analysts set for IMM?
1 brokers have issued 12 month price targets for ImmuPharma's stock. Their forecasts range from GBX 181 to GBX 181. On average, they anticipate ImmuPharma's share price to reach GBX 181 in the next year. This suggests a possible upside of 1,603.5% from the stock's current price. View Analyst Price Targets for ImmuPharma.
What is the consensus analysts' recommendation for ImmuPharma?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmuPharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ImmuPharma.
Has ImmuPharma been receiving favorable news coverage?
News headlines about IMM stock have trended positive this week, InfoTrie reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. ImmuPharma earned a coverage optimism score of 2.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the company's share price in the next few days.
Who are some of ImmuPharma's key competitors?
Some companies that are related to ImmuPharma include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE) and Ampliphi Biosciences (APHB).
Who are ImmuPharma's key executives?
ImmuPharma's management team includes the folowing people:
- Mr. Dimitri F. Dimitriou M.Sc., Co-Founder, CEO & Director (Age 56)
- Dr. D. Robert Henri Zimmer M.D., Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 70)
- Ms. Tracy Weimar BA, MBA, VP of Operations & Fin. and Company Sec.
- Dr. Jean-Marie Geiger PharmD, MD, Head of Clinical Devel.
- Mr. Nicholas Peter Kostopoulos, Lupuzor Director of Bus. Devel. - United States
How do I buy shares of ImmuPharma?
Shares of IMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is ImmuPharma's stock price today?
One share of IMM stock can currently be purchased for approximately GBX 10.63.
What is ImmuPharma's official website?
How can I contact ImmuPharma?
ImmuPharma's mailing address is 50 Broadway, LONDON, SW1H 0BL, United Kingdom. The company can be reached via phone at +44-20-71524080.
MarketBeat Community Rating for ImmuPharma (LON IMM)
MarketBeat's community ratings are surveys of what our community members think about ImmuPharma and other stocks. Vote "Outperform" if you believe IMM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMM will underperform the S&P 500 over the long term. You may vote once every thirty days.
